By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Immune Pharmaceuticals, Inc. 

150 Broadway
Suite 1801
New York  New York  10038  U.S.A.
Phone: 646-937-1941 Fax: n/a




Company News
Immune Pharma Announces The Launch Of REMAIN, An International Overall Survival Study With Ceplene And Low Dose Proleukin In Remission Maintenance In Acute Myeloid Leukemia 2/17/2017 7:40:19 AM
Immune Pharma Appoints New Chairman Of The Board Of Directors 1/27/2017 7:02:22 AM
Immune Pharma Enters A Research Partnership To Develop Mono- And Bispecific Antibodies Against Novel Targets In The Tumor Microenvironment 1/23/2017 9:59:04 AM
Immune Pharma Release: Company Will Request An Appeal To Regain Compliance With Nasdaq's Minimum Bid Price Rule 1/10/2017 6:47:10 AM
Immune Pharma Announces Immuno-Oncology R&D Update On December 8, 2016 11/22/2016 10:19:07 AM
Immune Pharma Secures Up To $11 Million In New Financing To Be Deployed With A Focus On Bertilimumab Clinical Development 11/17/2016 10:14:03 AM
Immune Pharma Receives FDA Guidance For Low Dose IL-2 In Combination With Phase III Pivotal Trial Of Its AML Therapy Ceplene 10/27/2016 6:44:41 AM
Immune Pharma Announces Formation Of Management Team For Maxim Pharmaceuticals, Inc. (MAXM), Its Pain And Neurology Subsidiary 10/17/2016 11:02:16 AM
Immune Pharma Signs Agreement To Fund Maxim Pharmaceuticals, Inc. (MAXM), Its Pain And Neurology Subsidiary 9/16/2016 8:41:28 AM
Immune Pharma Receives $2 Million Investment In Common Stock At $0.50 Per Share 9/7/2016 9:31:11 AM